National Institute of Health, R01, Principal Investiga

Prof. Dr. med. Jörg Köhl
Ausbildung
1980 – 1981
Studium der Biologie: Universität Mainz
1981 – 1982
Studium der Biologie: Universität Bochum
1982 – 1988
Studium der Humanmedizin: Universität Mainz und Promotion (Dr. med.)
Wissenschaftlicher Werdegang
1988 – 1991
Assistent in der Weiterbildung, Institut für Medizinische Mikrobiologie,
Medizinische Hochschule Hannover (MHH).
1991 – 1992
Assistent in der Weiterbildung, Abteilung Pulmonologie, MHH
1993 – 1994
Assistent in der Weiterbildung, Institut für Medizinische Mikrobiologie, MHH
1994
Facharzt für Medizinische Mikrobiologie und Infektionsepidemiologie
1995
Habilitation im Fach Medizinische Mikrobiologie; Ernennung zum Privatdozenten
1995
Oberarzt, Institut für Medizinische Mikrobiologie
1999
Ernennung zum apl. Professor
1999-2002
Leitender Oberarzt; Institut für Medizinische Mikrobiologie, MHH
1999-2002
Initiator
und
Sprecher
des
Transferbereichs
15:
Die
Bedeutung
des
Komplementspaltproduktes C3a als diagnostischer Frühmarker in der Sepsis.
2002-2008
Full Professor of Pediatrics (tenured), Division of Molecular Immunology,
Cincinnati Children’s Hospital Research Foundation, Cincinnati, USA
Seit April-2008
Adjunct Professor of Pediatrics, Division of Molecular Immunology, Cincinnati
Children’s Hospital Research Foundation, Cincinnati, USA
Seit April 2008
Direktor des Instituts für Systemische Entzündungsforschung, Medizinische
Fakultät der Universität zu Lübeck und des Universitätsklinikums SchleswigHolstein, Campus Lübeck.
Drittmitteleinwerbung
USA
A.
Thema:
Förderung:
Fördervolumen:
B.
Thema:
Förderung:
Fördervolumen:
Molecular regulation of immune complex disease
National Institute of Health, R01, Principal Investigator
(1 R01 AI59305-01A1) 2004 –2009
1.250.000 $ (Direct Costs)
Molecular regulation of immune complex disease
National Institute of Health, R021, Principal Investigator
(1 R21 AI59305-01) 2004-2005
250.000 $ (Direct Costs)
C.
Thema:
Förderung:
Fördervolumen:
D.
Thema:
Förderung:
Fördervolumen:
E.
Complement in allergic asthma: The role of C3a and C5a
National Institute of Health, R01, Principal Investgator
1 R01 (AI057839-01A1) 2004 - 2009
1.250.000 $ (Direct Costs)
The C5a receptor as a drug target in kidney transplantation
Translational Research Initiative (TRI) of CCHMC,
Principal Investigator
100.000 $
01/07/2005 – 30/06/2007
Förderung:
Improving the preservation effect of organ transplantation
solutions using the C5a receptor antagonist A8 71-73
Bridge the Gap Funding of CHMCC; Principal Investigator
Fördervolumen:
$100.000 $
Thema:
Δ
01/07/2006 – 30/06/2007
Deutschland
A.
Thema:
Leiter:
Förderung:
Zeitraum:
Fördervolumen:
1992 - 1994
1995 - 1997
1998 - 2000
B.
Thema:
Leiter:
Förderung:
Zeitraum:
Fördervolumen:
1994 - 1997
1997 - 2000
C.
Thema:
Leiter:
Förderung:
Zeitraum:
Fördervolumen:
Die pathophysiologische Rolle anaphylatoxischer Peptide.
Prof. Dr. J. Köhl, Prof. Dr. D. Bitter-Suermann (1992 -1997)
Prof. Dr. J. Köhl, Prof. Dr. Dr. W. Bautsch (1998 -2000)
DFG; Sonderforschungsbereich 244, Projekt B8
1992 - 2000
1 x BAT IIa; 1 x BAT IIa/2, 1 x BAT Vc;
118.800 DM Sachmittel
1 BAT IIa, 1 BAT Vb
129.000 DM Sachmittel; 54.600 DM Investitionsmittel
1 BAT IIa, 1 BAT Vb
130.000 DM Sachmittel
Generierung, Charakterisierung und Einsatz von C5a- und
C5aR-Antagonisten zur Blockade inflammatorischer Prozesse
von Entzündungszellen bei Rheumatischen Erkrankungen .
Prof. Dr. J. Köhl
BMBF-Verbundprojekt; Teilprojekt B1
1994 – 1997
1997 - 2000
BAT IIa/2; BAT Vc
105.000 DM Sachmittel
BAT IIa/2; BAT Vc
120.000 DM Sachmittel
Analyse humoraler und zellulärer Effektorsysteme bei der
Xenotransplantation
im
diskordanten
Kleintiermodell
Meerschweinchen/Ratte.
Prof. Dr. J. Köhl; Dr. Andreas Meyer zu Vilsendorf
DFG; Sonderforschungsbereich 265; Projekt B16
1998 - 2003
1998 – 2000
2001 – 2003
D.
Thema:
Sprecher:
Förderung:
Beteiligte Institutionen:
Beteiligtes Unternehmen:
Zeitraum:
Fördervolumen:
E.
Thema:
Leiter:
Förderung:
Zeitraum:
Fördervolumen:
F.
Thema:
Leiter:
Förderung:
Zeitraum:
Fördervolumen:
Thema:
Leiter:
Förderung:
Zeitraum:
Fördervolumen:
H.
Thema:
Leiter:
Förderung:
Zeitraum:
Fördervolumen
BAT IIa/2; BAT Vc
75.000 DM Sachmittel
BAT IIa
105.000 DM Sachmittel
Die Bedeutung des Komplementspaltproduktes C3a als
diagnostischer Frühmarker in der Sepsis.
Prof. Dr. J. Köhl
DFG; Transferbereich 15
Medizinische Hochschule Hannover
Unversitätsklinikum Magdeburg
Universitätsklinikum Heidelberg
Universitätsklinikum Mannheim
Universitätsklinikum München-Grosshadern
Biognosis GmbH; Jülich
März 1999 – Februar 2002
10 x BAT IIa/2; 1 x BAT Vc, 1 student. Hilfskraft
286.000 DM Sachmittel
davon 1 x BAT IIa/2, 1 x BAT Vc, 1 student. Hilfskraft und
209.000 DM Sachmittel im Institut für Med. Mikrobiologie
(Gesamtfördersumme: 1.970.000 DM)
Die pathogenetische Rolle von C5a und Fc gammaRezeptoren in Typ III und Typ IV Überempfindlichkeitsreaktionen.
Prof. Dr. J. Köhl
DFG-Normalverfahrten KO/1245 / 1-1
Oktober 2000 – September 2002
BAT IIa; BAT Vc; 122.000 DM Sachmittel
Die pathogenetische Rolle der Komplementspaltprodukte C3a und C5a bei der septischen Peritonitis
Prof. Dr. J. Köhl
DFG-Normalverfahrten KO/1245 / 2-1
März 2001 – Februar 2003
BAT IIa; 35.000 DM Sachmittel
Die Rolle der Anaphylatoxine C3a und C5a in der Pthognese des
experimentell-allergischen Asthmas.
Prof. Dr. J. Köhl
DFG; Transregio 22, Teilprojekt A21
Juli 2009 – Juni 2013
E13; E13/2; 120.000 Euro Sachmittel
The impact of sleep on immunoregulatory functions of
complement.
Prof. Dr. J. Köhl
DFG; SFB 654, Teilprojekt C7
Juli 2009 – Juni 2013
E13; 120.000 Euro Sachmittel
Eingeladene Vorträge (2004-01/2011)
1.
A dual role for complement in experimental allergic asthma. Fraunhofer seminar: Models
of asthma and COPD, January 21-22, 2011
2.
Novel roles for complement in the regulation of adaptive immunity 9th EFIS-EJI Tatra
Immunology Conference, Visegrad, Slovakia, September 4-8, 2010.
3.
Novel roles for complement in the regulation of adaptive immunity. 7th International
Conference on Innate Immunity, July 4-9, Rhodes, Greece.
4.
The role of complement at the interface between innate and adaptive immunity.
University of Greifswald, June 24, 2010.
5.
Novel roles for complement in the regulation of innate and adaptive immunity. Harvard
Medical School, Department of Medicine, April 28. 2010.
6.
The role of complement in immune complex diseases. XXXVII. Annual Meeting of the
ADF (Arbeitsgemeinschaft Dermatologische Forschung), Lübeck, 18.-20.02.2010
7.
The complex role of C5a in experimental goodpasture nephritis. 4thInternational
Workshop on Thrombotic Microangiopathies, Weimar, Germany, October 1-3, 2009.
8.
The role of complement at the interface between innate and adaptive immunity. Hycult
Biotechnology, The Netherlands, November 12, 2009
9.
Cross-talk beeetween IgG Fc and C5a receptors regulates neutrophilic inflammation in
immune complexe diseases. Neutrophil granulocytes revisited: International symposium
on novel functions of neutrophils granulocytes, Lübeck, Germany, September 10-12,
2009.
10. The complement system. 12th European Meeting on complement in human disseaes.
Visegrad, Hungary, September 5-8, 2009.
11. A novel role for C5L2 in the pathogenesis of anti-GBM nephritis. Session IV:
Complement”; 6th International Conference on Innate Immunity, Crete, Greece, June 2126, 2009
12. Complement: Sensor and effector system of innate and adaptive immune responses.
9thBeaune Seminar in Transplant Research: Transplantation tolerance induction at the
cross-roads between innate and adaptive immunity, Burgundy, May 13-15. 2009
13. Danger sensing by complement: the curious case of an anaphylatoxin receptor,
Department of Clinical Immunology, Uppsala University, March 19, 2009.
14. Danger sensing by complement: the curious case of an anaphylatoxin receptor, MRC
Centre for Transplantation at King’s College London, March 6, 2009.
15. The role of complement as a danger sensing system regulating adaptive immune
responses, 5th Spring School of Immunology, Kloster Ettal, March 2-6, 2009.
16. The role of complement as a danger sensing system regulating adaptive immune
responses, Institute of Medical Microbiology and Immunology, Aarhus, February 19,
2009.
17. The role of complement in danger sensing and transmission. University Ulm, Department
of Surgery III, February 17, 2009
18. Introduction to Complement and it's position in the immune system, XXIIst International
Complement Workshop, Keynote speaker, Teaching day: September 28 –October 2,
Basel, Switzerland, 2008
19. C5a receptor is part of a novel pathogen recognition system, Session IV: Complement”;
4th International Conference on Innate Immunity, June 4-9, Crete, Greece. 2008
20. C5a receptor is part of a novel pathogen recognition system. 4th International Conference
on Innate Immunity, June 21-26, Crete, Greece. Cross-talk of innate immune receptors.
13th International Congress of Immunology, Rio de Janeiro, Brazil, August 21-25, 2007.
21. The role of complement in danger sensing and transmission. 4th International Workshop
on Complement Associated Diseases, Animal Models, and Therapeutics, Porto Heli,
Greece, June 10-15, 2007.
22. Cross-talk of innate immune receptors. Washington University, St. Louis; Division of
Rheumatology, April 12-13, 2007.
23. Cross-talk between pattern recognition receptors systems. Cleveland Clinic, Department
of Pathobiology, February 26-27, 2007.
24. Immunoregulation at mucosal surfaces: cross-talk between complement and toll-like
receptors. University of Lübeck, February, 22-23, 2007.
25. Immunoregulation at mucosal surfaces: cross-talk between complement and toll-like
receptors. University of Münster, February, 20-21, 2007
26. Cross-talk between complement and TLRs. 35th Autumn Immunology Conference.
Symposium: Complement in Health and Disease., Chicago, November 18-20, 2006
27. Self, Non-Self and Danger: a complementary view. 4th International Conference on Innate
Immunity, Corfu Greece, June 4-9, 2006.
28. Allergy, infection and the adaptive immune response: a complementary view. University
of Irvine, CA, UCI Immunology Seminar Series, March 02, 2006.
29. Crossroads between Innate and Adaptive Immunity: The role of Complement. Archemix
Corporation, Cambridge, MA, USA, November 6, 2005.
30. C5a negatively regulates toll-like receptor 4-induced immune responses, University of
Jena, Germany, October 14, 2005
31. A critical role for complement in the sensitization and the effector phase of experimental
allergic asthma. Swiss Institute for Allergy and Asthma Research, Davos, Switzerland,
October 10, 2005
32. Complement in Inflammatory Disorders, 10th European Meeting on Complement in
Human Disease, Heidelberg, Germany, September 9-13, 2005.
33. Crossroads between Innate and Adaptive Immunity: The role of Complement, University
of Ulm, Germany, June 24, 2005
34. The role of complement in the regulation of adaptive immune responses. Jerini AG,
Berlin, Germany, May 5, 2005.
35. C5a regulates type 2 adaptive immunity in allergic asthma. “3rd Workshop on
Complement Associated Diseases, Animal Models, and Therapeutics” , Rhodes, Greece,
June 5-10, 2005
36. Cross-talk between complement and Toll-like receptors: complement 5a plays a crucial
gatekeeper role in TLR-4 mediated regulation of adaptive immunity. 3rd International
Conference on Innate Immunity, Crete, Greece, October 10-15, 2004
37. A critical role of C5a in the sensitization and the effector phase of experimental allergic
asthma. XXth International Complement Workshop, Hawaii, USA, June 13-18. 2004
38. Complement 5a mutants as complement 5a receptor antagonists: from phage display to
animal models. University of Maastricht, Department of General Surgery; The
Netherlands, March 2004.
39. Assessing the progression of the inflammatory response in SIRS and sepsis: The value of
measuring C3a, IL-6, and PCT. 6th World Congress on Trauma, Shock, Inflammation
and Sepsis – Pathophysiology, Immune Consequences and Therapy, Symposium XXIV,
Munich, Germany, March 2004.
40. Complement 5a mutants as complement 5a receptor antagonists: from phage display to
animal models. University of Frankfurt/Main, Department of Biochemistry, Germany,
March 2004.
41. Complement in allergic asthma: friend and foe. Immunological Colloquium Series,
Medical School Hannover, Germany, March 2004.
Reviewer für folgende Institutionen der Forschungsförderung (2004-2008)

Technology Foundation STW (Niederlande)

The Wellcome Trust (United Kingdom;)

The Eli and Edythe L. Broad Foundation (USA)

BioProfil Nutrigenomik (BMBF)

Deutsche Forschungsgemeinschaft (DFG)

Landesstiftung Baden-Württemberg

National Institute of Health (NIAID – HAI Study Section; Februar 2005)

National Institute of Health (NIAID – Special Emphasis Panel [ZRG1 IMM B ]
November 2005

National Institute of Health (NIAID – HAI Study Section; Februar 2006)

National Institute of Health (NIAID – Special Emphasis Panel [ZRG1 IMM B 02] Juli
2006